"Artemis Research is a leading Principal Investigator and Patient Focused clinical research company dedicated to advancing medical treatments through rigorous, process-driven trial management. Artemis specializes in Psychiatry/Neurology, Internal Medicine, and Women’s Health initiatives. Established in 2008 by colleagues who bring more than 50 years of combined research experience, the Artemis team is committed to a more thoughtful and professional approach to conducting clinical trials. We have multiple locations serving Southern California including San Diego, San Marcos, and Riverside."

During the past decade, Artemis Institute for Clinical Research conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 85 clinical trials were completed, i.e. on average, 64.4% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 64 clinical trials were completed. i.e. 116.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Artemis Institute for Clinical Research" #1 sponsor was "Eli Lilly and Company" with 30 trials, followed by "Pfizer" with 12 trials sponsored, "Sunovion" with 10 trials sponsored, "Naurex, Inc, an affiliate of Allergan plc" with 8 trials sponsored and "Allergan" with 8 trials sponsored. Other sponsors include 89 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Artemis Institute for Clinical Research" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "H. Lundbeck A/S" with 2 trials as a collaborator, "PPD" with 2 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Artemis Institute for Clinical Research" are "Major Depressive Disorder" (13 trials), "Schizophrenia" (13 trials), "Depressive Disorder, Major" (11 trials), "Migraine" (8 trials) and "Alzheimer's Disease" (6 trials). Many other conditions were trialed in "Artemis Institute for Clinical Research" in a lesser frequency.

Most popular intervention types in "Artemis Institute for Clinical Research" are "Drug" (141 trials), "Other" (16 trials), "Biological" (14 trials), "Device" (3 trials) and "Genetic" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (87 trials), "Rapastinel" (6 trials), "Dulaglutide" (4 trials), "Tirzepatide" (4 trials) and "Galcanezumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Artemis Institute for Clinical Research" are 157 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Artemis Institute for Clinical Research". undefined are not yet recruiting, 14 are recruiting, 14 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 110 completed trials in Artemis Institute for Clinical Research, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Artemis Institute for Clinical Research, 2 "Phase 1" clinical trials were conducted, 67 "Phase 2" clinical trials and 85 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 5 trials that are defined as “Not Applicable".